Manuel Vázquez Carrera
Jefe de Grupo Senior
The researcher Manuel Vázquez Carrera graduated in Pharmacy in 1990 from the University of Barcelona and received his Doctor of Pharmacology degree from the University of Barcelona in 1994.
Between 1996 and 2001 he spent a postdoctoral stay at the Institut de Biologie Animale de la Université de Lausanne where he studied the mechanisms of action of the nuclear receptor PPARα.
In 1997 he got a position of full professor at the University of Barcelona and since 2017 he has been full professor of the same university. However, he is a principal researcher at CIBERDEM.
He is currently leading the research group Pharmacological Targets for Inflammation and Metabolic Diseases, where he studies the mechanisms involved in the relationship between inflammation and the development of insulin resistance and diabetic cardiomyopathy.
Professional network profiles
Last Publications
- Palomer FX, Wang JR, Escalona C, Wu S, Wahli W and Vazquez M Targeting AMPK as a potential treatment for hepatic fibrosis in MASLD. TRENDS IN PHARMACOLOGICAL SCIENCES . 46(6): 551-566.
- Rostami A, Palomer X, Pizarro J, Peña L, MATIAS ZAMORA RODRÍGUEZ, Montori M, Barroso E, Valenzuela-Alcaraz BI, Crispi F, Salvador JM, García R, Hurlé MA, Nistal F and Vazquez M GADD45A suppression contributes to cardiac remodeling by promoting inflammation, fibrosis and hypertrophy CELLULAR AND MOLECULAR LIFE SCIENCES . 82(1): 189-189.
- Girona J, Guardiola M, Barroso E, García-Altares M, Ibarretxe D, Plana N, Ribalta J, Amigó N, Correig X, Vazquez M, Masana L and Rodríguez-Calvo R GDF15 Circulating Levels Are Associated with Metabolic-Associated Liver Injury and Atherosclerotic Cardiovascular Disease. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES . 26(5): .
News
-
Researchers discover a new promising strategy to halt the progression of liver fibrosis
The new work, published in the journal Biomedicine & Pharmacotherapy, has been led by Manuel Vázquez Carrera, head of the research group Pharmacological Targets in Inflammation and Metabolic Diseases at the Sant Joan de Déu Research Institute (IRSJD) and the Biomedical Research Centre in Diabetes and Associated Metabolic Diseases (CIBERDEM) at the University of Barcelona.
-
New Therapeutic Targets to Fight Type 2 Diabetes
A study led by Dr Manuel Vázquez-Carreras presents an integrative view of the most outstanding advances in understanding this process and helping to identify new pharmacological targets in the fight against type 2 diabetes mellitus.
-
Metformin, key drug in the battle against type 2 Diabetes, reveals its secrets in a new study
Dr. Manuel Vázquez-Carrera, Institut de Recerca Sant Joan de Déu (IRSJD) and professor from the Faculty of Pharmacy and Food Sciences of the University of Barcelona, leads this new study on metformin, one of the most prescribed drugs for treating type 2 diabetes mellitus.